{
    "nctId": "NCT03748550",
    "briefTitle": "Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)",
    "officialTitle": "EXercise to Prevent AnthraCycline-based Cardio-Toxicity 2.0 (EXACT2) in Individuals With Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Cancer, Breast, Cardiotoxicity, Cardiovascular Diseases",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Change in Left Ventricular (LV) Function",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1) must be 18 years or older.\n* diagnosed with breast cancer (stages I-III) and not have started therapy.\n* must be scheduled to receive AC- based chemotherapy (minimum dose of 240 mg/m2 of DOX or 300 mg/m2 of DAN).\n* are able to undertake a 12-week home-based, progressive aerobic exercise program.\n* have medical clearance from a cardiologist (e.g. based on stress test results) to participate in the study.\n\nExclusion Criteria:\n\n* significant cognitive limitations.\n* pre-existing medical condition that would otherwise contraindicate aerobic exercise.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}